- Home
- Publications
- Publication Search
- Publication Details
Title
Mammalian Target of Rapamycin (mTOR) Inhibitors
Authors
Keywords
-
Journal
DRUG SAFETY
Volume 34, Issue 2, Pages 97-115
Publisher
Springer Nature
Online
2011-01-20
DOI
10.2165/11585040-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization
- (2010) Duk-Woo Park et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anaemia, microcytosis and sirolimus--is iron the missing link?
- (2010) S. Sofroniadou et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial
- (2010) Robert Applegate et al. EuroIntervention
- The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential
- (2009) Hiroyuki Mori et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome
- (2009) David T. Teachey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hepcidin--A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease
- (2009) J. Zaritsky et al. Clinical Journal of the American Society of Nephrology
- Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients
- (2009) S. Demirjian et al. CLINICAL TRANSPLANTATION
- Posttransplant anemia: the role of sirolimus
- (2009) Steven Fishbane et al. KIDNEY INTERNATIONAL
- Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease
- (2009) A. L. Serra et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- A Novel Immunological Assay for Hepcidin Quantification in Human Serum
- (2009) Vasiliki Koliaraki et al. PLoS One
- Obesity Increases Vascular Senescence and Susceptibility to Ischemic Injury Through Chronic Activation of Akt and mTOR
- (2009) C.-Y. Wang et al. Science Signaling
- Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS
- (2009) Hongyan Li et al. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
- Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
- (2008) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Immunoassay for human serum hepcidin
- (2008) T. Ganz et al. BLOOD
- Quantification of Hepcidin-25 in Human Serum by Isotope Dilution Micro-HPLC-Tandem Mass Spectrometry
- (2008) U. Kobold et al. CLINICAL CHEMISTRY
- Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies
- (2008) Monica M. Mita et al. JOURNAL OF CLINICAL ONCOLOGY
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
- (2008) John J. Bissler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduction in Erythropoietin Resistance After Conversion From Sirolimus to Enteric Coated Mycophenolate Sodium
- (2008) Joshua J. Augustine et al. TRANSPLANTATION
- Effects of Everolimus Monotherapy on Hematological Parameters and Iron Homeostasis in De Novo Liver Transplant Recipients: Preliminary Results
- (2008) M. Masetti et al. TRANSPLANTATION PROCEEDINGS
- Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study
- (2007) G A W Bruyn et al. ANNALS OF THE RHEUMATIC DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started